Surprisingly, A3B expression was associated with poor patient survival in ER+ breast cancer, but not in ER− breast cancer, despite the fact that A3B expression was higher in ER− breast cancer than in ER+ breast cancer, thus implicating A3B in ER action. This evidence concerns the gene APOBEC3B and breast cancer.